FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focused on developing therapeutics using fibroblasts and fibroblast-derived materials, will participate in the H.C.

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focused on developing therapeutics using fibroblasts and fibroblast-derived materials, will participate in the H.C. Wainwright 27th Annual Global Investment Conference.

The company's CEO, Pete O'Heeron, will deliver a presentation on September 10 at 12:00 p.m. ET at the Lotte New York Palace Hotel. The company, which holds over 275 patents issued and pending, will also be available for one-on-one meetings with investors during the conference.

Argus Aug 27 session

-0.86% close to close Open Argus

Details

News Market Reaction – FBLG

On Aug 27, the day this news came out, FBLG closed 0.86% below the previous close.

Data tracked by StockTitan Argus for the Aug 27 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the H.C. Wainwright 27^th Annual Global Investment Conference taking place September 8-10 at the Lotte New York Palace Hotel in New York City.

FibroBiologics will deliver a company presentation at 12:00 p.m. ET on September 10 and be available for one-on-one investor meetings throughout the event.

For more information, please visit FibroBiologics’ website or email FibroBiologics at info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is FibroBiologics (FBLG) presenting at the H.C. Wainwright Conference?

FibroBiologics will present on September 10, 2025, at 12:00 p.m. ET at the Lotte New York Palace Hotel in New York City.

Who will be presenting for FibroBiologics at the H.C. Wainwright Conference?

Pete O'Heeron, the Founder and Chief Executive Officer of FibroBiologics, will deliver the company presentation.

How many patents does FibroBiologics (FBLG) have?

FibroBiologics has 275+ patents issued and pending related to fibroblasts and fibroblast-derived materials.

What is FibroBiologics' (FBLG) main focus as a company?

FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.

Where can investors get more information about FibroBiologics' presentation?

Investors can visit FibroBiologics' website or email the company at info@fibrobiologics.com for more information.